Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Presbycusis | 8 | 2017 | 11 | 1.900 |
Why?
|
| Temporal Bone | 10 | 2014 | 66 | 1.670 |
Why?
|
| Spiral Ganglion | 9 | 2017 | 25 | 1.300 |
Why?
|
| Cochlea | 7 | 2017 | 48 | 0.970 |
Why?
|
| Aging | 3 | 2017 | 659 | 0.810 |
Why?
|
| Otosclerosis | 2 | 2014 | 6 | 0.770 |
Why?
|
| Receptors, Estrogen | 2 | 2016 | 376 | 0.620 |
Why?
|
| Vestibular Nerve | 1 | 2017 | 32 | 0.620 |
Why?
|
| Goldfish | 1 | 2016 | 6 | 0.610 |
Why?
|
| Vitellogenins | 1 | 2016 | 10 | 0.610 |
Why?
|
| Taxoids | 1 | 2016 | 129 | 0.590 |
Why?
|
| Protein Precursors | 1 | 2016 | 143 | 0.590 |
Why?
|
| Hydroxycholesterols | 1 | 2016 | 6 | 0.580 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2016 | 31 | 0.570 |
Why?
|
| Cadherins | 1 | 2016 | 149 | 0.570 |
Why?
|
| Biological Assay | 1 | 2016 | 77 | 0.570 |
Why?
|
| Stria Vascularis | 2 | 2006 | 5 | 0.550 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 142 | 0.550 |
Why?
|
| Collagen Type I | 2 | 2014 | 62 | 0.530 |
Why?
|
| Keratan Sulfate | 1 | 2014 | 6 | 0.520 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 133 | 0.520 |
Why?
|
| Chondroitin Sulfates | 1 | 2014 | 43 | 0.510 |
Why?
|
| Thyroid Hormones | 1 | 2016 | 308 | 0.500 |
Why?
|
| Cholesterol | 1 | 2016 | 352 | 0.500 |
Why?
|
| Cell Membrane | 1 | 2016 | 660 | 0.480 |
Why?
|
| Cell Movement | 1 | 2016 | 737 | 0.470 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 2831 | 0.440 |
Why?
|
| Cochlear Nucleus | 1 | 2011 | 6 | 0.440 |
Why?
|
| DNA, Mitochondrial | 5 | 2011 | 181 | 0.430 |
Why?
|
| Cellular Senescence | 1 | 2011 | 94 | 0.410 |
Why?
|
| Liver | 1 | 2016 | 1203 | 0.410 |
Why?
|
| Hearing Loss, Sensorineural | 3 | 2004 | 46 | 0.390 |
Why?
|
| Obesity | 2 | 2016 | 939 | 0.370 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1441 | 0.340 |
Why?
|
| Hair Cells, Vestibular | 1 | 2005 | 17 | 0.280 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2324 | 0.270 |
Why?
|
| Audiometry | 4 | 2011 | 16 | 0.270 |
Why?
|
| RNA Interference | 2 | 2016 | 361 | 0.270 |
Why?
|
| Female | 15 | 2017 | 43674 | 0.260 |
Why?
|
| Cell Death | 3 | 2016 | 254 | 0.250 |
Why?
|
| Microdissection | 4 | 2011 | 18 | 0.240 |
Why?
|
| Hair Cells, Auditory | 3 | 2017 | 23 | 0.230 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1736 | 0.220 |
Why?
|
| Cochlear Nerve | 1 | 2001 | 9 | 0.220 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2011 | 309 | 0.200 |
Why?
|
| Humans | 25 | 2017 | 83765 | 0.200 |
Why?
|
| Organ of Corti | 3 | 2006 | 10 | 0.190 |
Why?
|
| Male | 13 | 2017 | 40172 | 0.190 |
Why?
|
| Retrospective Studies | 6 | 2014 | 8055 | 0.180 |
Why?
|
| Aged | 11 | 2017 | 18030 | 0.180 |
Why?
|
| Collodion | 2 | 2008 | 7 | 0.170 |
Why?
|
| Sequence Deletion | 2 | 2010 | 204 | 0.170 |
Why?
|
| Gene Deletion | 2 | 2011 | 327 | 0.170 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 6422 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 863 | 0.160 |
Why?
|
| Cell Count | 1 | 2017 | 192 | 0.150 |
Why?
|
| Hearing | 1 | 2017 | 59 | 0.150 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 181 | 0.150 |
Why?
|
| Mice, SCID | 1 | 2016 | 237 | 0.150 |
Why?
|
| Lead | 1 | 2016 | 24 | 0.150 |
Why?
|
| Lasers | 3 | 2011 | 103 | 0.140 |
Why?
|
| Estrogen Antagonists | 1 | 2016 | 47 | 0.140 |
Why?
|
| Crime | 1 | 2016 | 35 | 0.140 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2016 | 158 | 0.140 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 104 | 0.140 |
Why?
|
| Environmental Pollutants | 1 | 2016 | 48 | 0.140 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 268 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2016 | 278 | 0.140 |
Why?
|
| Workflow | 1 | 2016 | 74 | 0.140 |
Why?
|
| Middle Aged | 9 | 2014 | 24628 | 0.140 |
Why?
|
| Age of Onset | 1 | 2016 | 302 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 448 | 0.140 |
Why?
|
| Atrophy | 2 | 2006 | 76 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 461 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 522 | 0.130 |
Why?
|
| Triiodothyronine | 1 | 2016 | 322 | 0.130 |
Why?
|
| Ligands | 1 | 2016 | 422 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 309 | 0.130 |
Why?
|
| Age Factors | 2 | 2011 | 1817 | 0.130 |
Why?
|
| Transfection | 1 | 2016 | 882 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2016 | 698 | 0.120 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 2380 | 0.120 |
Why?
|
| Reference Values | 2 | 2011 | 673 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1948 | 0.120 |
Why?
|
| Adult | 9 | 2011 | 25194 | 0.110 |
Why?
|
| Tissue Embedding | 2 | 2011 | 6 | 0.110 |
Why?
|
| Autopsy | 1 | 2011 | 102 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 921 | 0.110 |
Why?
|
| Skull Neoplasms | 1 | 1991 | 30 | 0.100 |
Why?
|
| Cytochrome-c Oxidase Deficiency | 1 | 2010 | 3 | 0.100 |
Why?
|
| Proteoglycans | 1 | 2011 | 118 | 0.100 |
Why?
|
| Child | 5 | 2016 | 6705 | 0.100 |
Why?
|
| Cell Separation | 1 | 2011 | 192 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1943 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1181 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 153 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2011 | 1778 | 0.090 |
Why?
|
| Stapes Surgery | 1 | 1989 | 6 | 0.090 |
Why?
|
| Time Factors | 2 | 2016 | 5176 | 0.090 |
Why?
|
| Cadaver | 2 | 2011 | 181 | 0.090 |
Why?
|
| Proteomics | 1 | 2010 | 201 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2011 | 316 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 228 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 260 | 0.080 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 23 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2008 | 119 | 0.080 |
Why?
|
| Hearing Loss | 1 | 2008 | 51 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1747 | 0.080 |
Why?
|
| Animals | 2 | 2016 | 26003 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2008 | 257 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2016 | 3568 | 0.070 |
Why?
|
| Adolescent | 4 | 2011 | 8806 | 0.070 |
Why?
|
| Risk Factors | 1 | 2016 | 5301 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 1967 | 0.070 |
Why?
|
| Linear Models | 1 | 2006 | 411 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 231 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 1155 | 0.060 |
Why?
|
| Citalopram | 1 | 2003 | 20 | 0.060 |
Why?
|
| Neurons | 1 | 2011 | 1490 | 0.060 |
Why?
|
| Bulimia | 1 | 2003 | 139 | 0.060 |
Why?
|
| Tobramycin | 1 | 2001 | 10 | 0.050 |
Why?
|
| Gentamicins | 1 | 2001 | 18 | 0.050 |
Why?
|
| Deafness | 1 | 2001 | 47 | 0.050 |
Why?
|
| Cochlear Implantation | 1 | 2001 | 31 | 0.050 |
Why?
|
| Apoptosis | 1 | 2008 | 1667 | 0.050 |
Why?
|
| Young Adult | 1 | 2011 | 5839 | 0.050 |
Why?
|
| Electron Transport Complex IV | 2 | 2008 | 47 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2011 | 741 | 0.040 |
Why?
|
| Missouri | 1 | 2016 | 19 | 0.040 |
Why?
|
| Cities | 1 | 2016 | 41 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2016 | 280 | 0.030 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2011 | 73 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2011 | 38 | 0.030 |
Why?
|
| Petrous Bone | 1 | 1991 | 11 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 73 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2011 | 82 | 0.030 |
Why?
|
| Ear, Middle | 1 | 1991 | 22 | 0.030 |
Why?
|
| Fixatives | 1 | 2010 | 13 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2011 | 163 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2010 | 40 | 0.020 |
Why?
|
| Formaldehyde | 1 | 2010 | 53 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 917 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 207 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 348 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 154 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2322 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 86 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 207 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 2009 | 16 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 268 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 199 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 2993 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 540 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 315 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2011 | 297 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 296 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 650 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 537 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 586 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 2312 | 0.020 |
Why?
|
| Titrimetry | 1 | 2003 | 15 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 3618 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 3024 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2003 | 213 | 0.010 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2001 | 23 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 2649 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2001 | 246 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1747 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 3179 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 3884 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2003 | 764 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 883 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 1797 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2003 | 2413 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 2390 | 0.010 |
Why?
|